Castle Biosciences DecisionDx®-Melanoma Test Receives 2022 MedTech Breakthrough Award – Consumer Electronics Net consumerelectronicsnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from consumerelectronicsnet.com Daily Mail and Mail on Sunday newspapers.
Message :
Required fields
BRIDGEWATER, N.J., May 10, 2021 (GLOBE NEWSWIRE) RVL Pharmaceuticals, Inc., a subsidiary of Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica”), a fully integrated biopharmaceutical company, today announced that its
® (oxymetazoline hydrochloride ophthalmic solution), 0.1% has been selected as the winner of the “Best New Technology Solution for Drug Delivery” award in the fifth annual MedTech Breakthrough Awards program conducted by
MedTech Breakthrough, an independent market intelligence organization that recognizes the top companies, technologies and products in the global health and medical technology market.
Upneeq
® provides patients and eye care providers with a safe and convenient non-surgical option to treat adults with acquired blepharoptosis (ptosis). The FDA-approved eye drop is the first and only therapeutic approved for the condition which previously required a surgical procedure. Upneeq
Share this article
Share this article
SAN DIEGO, May 6, 2021 /PRNewswire/ Mindera Corporation today announced that it has been selected as the winner of the Best New Technology Solution for Dermatology award in the fifth annual MedTech Breakthrough Awards program conducted by MedTech Breakthrough, an independent market intelligence organization that recognizes the top companies, technologies and products in the global health and medical technology market.
Mindera, winner of the 2021 Medtech Breakthrough Award
The Mindera platform uses a simple patch that takes only minutes to extract biomarkers, allowing for simple, minimally invasive, rapid and painless extraction of RNA from the skin using a dermal biomarker patch. Subsequent Next-Generation Sequencing of the extracted RNA allows Mindera scientists to take a genetic and transcriptomic snapshot of the skin at the exact moment of the test. This rich patient-specific data set is then analyzed by machine learning algorithms t